MI-CP151 was a phase 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre analyze To judge numerous intravenous doses of sifalimumab, in adult patients with dermatomyositis or polymyositis (NCT00533091). Major trial goals were being To judge the safety and tolerability of sifalimumab in dermatomyositis or polymyositis individuals, when one of the exploratory https://avibactamsodium32109.imblogs.net/80566815/the-basic-principles-of-parp-1-in-3